The healthcare and life sciences industry in Catalonia has 734 companies and 89 research bodies.
- Turnover and employment: The companies in the sector post yearly turnover of €14.36 billions, 7% of the GDP of Catalonia (2014 data) and employ 42,133 workers. These figures are up 24% and 25%1, respectively from the 2013 Report.
- Investment: Between 2013 and 2015, companies in the BioRegion attracted more than €100 millions in investment, more than half over the past year, with large operations like the Oryzon-Roche and Palobiofarma-Novartis deals or the Minoryx Therapeutics and Sanifit rounds of funding, led by the main Catalan venture capital funds Ysios Capital and Caixa Capital Risc.
- Creation of companies: Between 2013 and September 2015, 75 new companies were set up in the BioRegion, 14% more than the previous period.
- R&D Investment: public and private investment in R&D in Catalonia dropped nearly 11% between 2009 (which was the turning point after a decade of steady growth) and 2014. Nevertheless, R&D expenditure makes up 1.47% of the Catalan GDP (data from 2014), which is above the Spanish average (1.23%). Moreover, Catalonia leads R&D investment in biotechnology in Spain, with a total spending of €416 millions (28.7% of the total) (2014 data).
- Scientific excellence: Catalonia is awarded 53% of the grants from the European Research Council (ERC) to go to scientists in Spain (180), 35% of which go to life sciences. Regarding scientific production in life sciences, Catalonia produces 3.15% of all scientific production in Europe and 0.99% in the world, and 29% of publications in Spain.
- Research personnel: In Catalonia, there are 43,898 people working in R&D (in all sectors), 25,474 of which are researchers. One in five researchers (21%) in Spain work in Catalonia.
- Students: the 11 Catalan universities that offer health and life sciences degrees graduate 5,500 students each year. Three of these universities (UAB, UPF and UB) are among the top 200 in the world (Times Higher Education ranking, 2015).
- Hospitals: Catalonia has 15 university hospitals and 9 associated research institutes, where 5,000 researchers work.
Companies in the BioRegion: joint figures for the sector
- Turnover: in 2014, the 734 companies in the BioRegion posted revenue of €14.36 billions, of which:
- €6.85 billions was from pharmaceutical companies (48%)
- €2.91 billions from biotechnology companies (20%), the segment that saw the greatest growth compared to 2011
- €3.09 billions from medical technology companies (22%)
- €1.51 billions from other companies (€16 millions from digital health companies)
- GDP: Companies in the BioRegion account for 7% of the GDP of Catalonia (up 1.2% from the 2013 Report).
- Funding and investment: between 2013 and 2015, companies in the BioRegion attracted more than €100 millions in investment, more than half (€55.16 millions) in 2015.
- According to ASCRI2, Catalonia is home to 38% of all companies in any sector to receive investment in 2014, with 60% of all capital invested. In the biosciences, the €10 millions raised by Catalan companies makes up 36% of all venture capital invested in Spain in 2014.
- Main operations:
- Oryzon-Roche licensing agreement valued at $500 millions
- Deal to transfer Almirall respiratory division to AstraZeneca for €1.56 billions
- Palobiofarma-Novartis licensing agreement valued at €13 millions
- Merger of Reig Jofre and Natraceutical, and later IPO on Spanish Continuous Market (sixth biopharmaceutical company to go public after Almirall, Grifols, Faes Farma, Oryzon and Rovi)
- Grifols purchase of the Novartis hematology diagnostic division valued at $1.67 billions, acquisition of 50% of Kiro Robotics and 45% of Alkahest
- Large rounds of funding:
- Oryzon: €16.5 millions (2015)
- Minoryx Therapeutics: €19.4 millions (2015)
- TopDoctors, Clinic Point, Medtep, Galgo Medical: about €1 million each (2015)
- Ysios Capital led the largest round of funding in a Spanish biotech firm, Sanifit, valued at €36.6 millions
- The BioRegion has 26 investment bodies, noteworthy among which are:
- 8 venture capital firms, 4 of which specialize in the sector with significant investment volume: Caixa Capital Risc, Ysios Capital, Inveready and HealthEquity.
- 7 associations of business angels.
- 4 corporate investors.
- 1 institutional investor (Catalan Institute of Finance, ICF).
- 3 new crowdfunding and crowdequity initiatives.
- Business creation: between 2013 and 2015, 75 new companies were set up in the BioRegion, most of which are biotechnology firms (27), up nearly 14% from the 2013 report, with a predominance of those offering R&D services (14).
- There is a significant group of new consulting and professional services companies (17) and medical technology firms (14).
- Between 2005 and 2015, 337 new business projects were launched in the BioRegion. Over the same period, only 9% of the projects have had to close down (compared to the mortality rate of innovative companies in Spain and in Catalonia, which is nearly 50%).
- Employment: companies in the life sciences sector employ 42,133 workers (up 25% from the 2013 Report), an estimated 4,000 of which work in R&D.
- Size: 88% of the companies in the BioRegion are SMEs. Nearly half of these are microenterprises with fewer than 10 workers and annual operating income under €2 millions. Over the past two years, the number of medium-sized companies (between 50 and 250 workers and annual revenue of between €10 millions and €50 millions) has doubled and accounts for 22% of all companies, which is a sign of progressive consolidation in the sector.
- Internationalization: the main market for Catalan life sciences companies continues to be Spain. Europe is the main destination for exports and international marketing (mainly Germany, Italy and France) along with the United States.
- Location: the province of Barcelona is home to 95% of the business fabric in the life sciences sector in Catalonia; the capital concentrates 51% of the sector and 81% of investors.
Companies in the BioRegion, by subsector3
The BioRegion has 734 companies: 221 biotechnology, 46 pharmaceutical, 94 innovative medical technology, 208 suppliers and engineering firms, 130 consulting and professional services and 26 active investment organizations.
- The BioRegion has 221 biotechnology companies, of which:
- 45 do research and development into new therapies and diagnostic tools, mainly focusing on the following areas of activity: research into peptides and proteins, often linked to new drug delivery solutions and the production of antibodies.
- 92 specialize in R&D services, mainly in the following areas of activity: CRO (contract research organizations), analytical services and diagnostics. Growth in genomics and diagnostic instruments has been noteworthy.
- 84 develop products and services in areas including veterinary health, agriculture, food, cosmetics and transforming industrial processes.
Catalonia is the leading region in Spain in the number of biotechnology companies and businesses that use biotechnology (followed by Madrid and Andalusia).
- The BioRegion has 46 pharmaceutical companies:
- The main areas of activity of those who work in therapies and diagnostics are: generics, small molecules and anti-infective drugs.
The main therapeutic areas in which biotech and pharma companies work are: cancer (often focusing on rare diseases) and neoplasms, dermatology, infectious diseases, and diseases of the nervous system and the respiratory system.
- The BioRegion has 200 medical technology companies4, of which:
- 94 research, develop, manufacture and market medical devices and systems named “innovative”. Their main areas of activity are: producing reusable instruments, dental devices and electromagnetic devices.
- 93 are distributors, produce medical instruments, manufacture laboratory equipment and fungibles, engineering firms and electronics companies.
- 11 are biotechnology companies that produce and distribute in vitro diagnostic devices (IVD).
- 2 provide information technology services.
- The BioRegion has 40 companies working in digital health5:
- These companies work in:
- bioinformatics and computational research
- medical visits or appointments
- monitoring and following up on patients
- medical imaging and virtual reality
- personalized cognitive services and patient services
- software solutions
- The BioRegion has 89 research bodies and facilities: 41 research centers (32 of which are CERCA centers), 15 university hospitals, 11 universities that offer life sciences degrees; 2 large science facilities; 7 technology centers and 13 science and technology parks with activity in the life sciences.
- Scientific production: Catalonia contributes 0.99% of all global scientific production in the health and life sciences.
- The number of health and life sciences publications has increased 168% between 2000 and 2015, making up 3.15% of all scientific production in Europe.
- Catalonia produces 27% of all scientific publications in Spain. From 2007 to 2015, the region has obtained 53% of all ERC grants awarded to scientists in Spain. Of these 180 grants, 62 went to the life sciences.
- Patents: between 2010 and 2015, 286 patent applications in healthcare and life sciences were generated in Catalonia and filed with the OEPM (Spanish Patent and Trademark Office), 17% of the total nationwide.
- Research groups: Catalonia has 780 research groups in the healthcare and life sciences, which is 47% of the 1,652 consolidated research groups recognized in the 2014-2016 call.
- Spin-offs: between 1992 and 2015, 92 life sciences spin-offs were created, 85 of which are still active (2015).
- Mergers and groupings: in 2014, a process began to group together separate entities under a shared banner in order to gain critical mass and boost competitiveness by taking advantage of the synergies at different research institutes. The results of these mergers are as follows:
- BIST (Barcelona Institute of Science and Technology): an initiative that brings together 6 large research centers (CRG, ICIQ, ICN2, ICFO, IFAE, IRB)
- EURECAT: merger of 6 large technology centers (ASCAMM, Barcelona Media, BDigital, CETEMSA, CTM, CTNS)
- Integration of CRESIB and CREAL into ISGlobal
- Integration of CReSA into IRTA
- Integration of ICCC into the Research Institute of the Sant Pau Hospital
- Merger of IMPPC, IJC and IGTP
- New initiatives:
- BCTP (Barcelona Clinical Trials Platform): a platform fostered by Biocat and the Government to improve the coordination, integration, quality, inclusiveness and speed of clinical research, bringing together the 8 most important institutes in Catalonia by volume of clinical trials.
- I3PT (Parc Taulí Institute of Health Research and Innovation): an initiative promoted by the Parc Taulí Health Corporation, Sabadell Service Centre for the Elderly, UDIAT Diagnostics Centre, the Parc Taulí Foundation and the Autonomous University of Barcelona, which have signed an agreement with the aim of using this formula to join the nationwide map of health research institutes accredited by the Institute of Health Carlos III and join the ranks of CERCA centers.
- BIB (Bioinformatics Barcelona): an association that aims to act as a catalyst for initiatives in advanced research, knowledge transfer and technology in the field of biomedicine.
- Employment: The 41 research centers working in the biosciences and related fields have a joint total of 8,716 people on staff, 5,499 of which are researchers.
- Budget: the CERCA centers (44 centers, 32 of which work on life sciences) have a joint annual budget of €400 millions. The Government of Catalonia contributes approximately 40% of these resources.
- Health and life sciences graduates: approximately 5,500 students/year
- R&D Budget: in 2013, they saw €187 millions, a figure that has dropped since 2010. 65% came from competitive calls: 47% from national calls (a percentage that is decreasing) and 53% from European calls (making up an ever-greater proportion).
- Transfer: Catalan universities generated 59% of all life sciences spin-offs active in 2015 (50 companies).
[UNIVERSITY HOSPITALS AND ASSOCIATED RESEARCH INSTITUTES]
- Composition: the Catalan hospital system has 195 establishments, 65 publicly owned hospitals (13 of which are university hospitals), 36 private (2 of which are university hospitals), 62 social health centers (government subsidized), 17 psychiatric and/or social health centers (with or without government subsidies) and 15 psychiatric centers (subsidized).
- Employment: as a whole, these centers employ more than 89,000 workers, approximately one third of which are at the 15 university hospitals.
- The 15 hospitals and 9 associated research institutes employ about 5,000 researchers.
- Scientific production: the hospitals and their research institutes produce 32% of all scientific publications (2007-2011), have 24% of all accredited research groups in the health and life sciences and generate 7% of all patent applications filed with the OEPM (2014).